Rubén Spretz
Rubén Spretz publishes mostly in Genetics, Molecular Biology and Immunology, on topics such as Chronic Lymphocytic Leukemia Research, Nanoparticle-Based Drug Delivery and Lymphoma Diagnosis and Treatment.
- World rank
- #2,440,532 of 7,710,434 ranked researchers
- Rank in United States
- #722,118 of 1,627,098
- Works
- 42
- Citations
- 795
- Citations per work
- 18.9
What does Rubén Spretz research?
Rubén Spretz's work is mostly in Medicine (29%), Biochemistry, Genetics and Molecular Biology (12%), Immunology and Microbiology (12%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else1639.1%
- Health Sciences1229.2%
- Medicine1229.2%
- Life Sciences1024.4%
- Physical Sciences37.3%
- Materials Science37.3%
- 1Genetics15% of their works
- 2Molecular Biology12% of their works
- 3Immunology12% of their works
- 4Public Health, Environmental and Occupational Health7% of their works
- 5Biomaterials7% of their works
- 6Pathology and Forensic Medicine7% of their works
Research topics
- Chronic Lymphocytic Leukemia Research
- Nanoparticle-Based Drug Delivery
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Characterization and Applications of Magnetic Nanoparticles
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related molecular mechanisms research
Which keywords describe Rubén Spretz's research?
The keywords of their largest research topics: Prognostic Factors, Rituximab, Biomedical Applications, Nanoparticles, Chronic Lymphocytic Leukemia, Genomic Aberrations, Acute Lymphoblastic Leukemia and Childhood Cancer.
- Long Noncoding RNAs
- Therapeutic Antibodies
- Immunity
- Fc Receptors
- Nanocarriers
- Drug Delivery
- Childhood Cancer
- Genomic Aberrations
- Nanoparticles
- Rituximab
- Prognostic Factors
- Biomedical Applications
- Chronic Lymphocytic Leukemia
- Acute Lymphoblastic Leukemia
- Classification
- Lymphoma
- Dendritic Cells
- Ferrofluids
- Magnetic Particle Imaging
- Cancer
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Prognostic Factors72 topics
- Rituximab72 topics
- Biomedical Applications52 topics
- Nanoparticles52 topics
- Chronic Lymphocytic Leukemia41 topic
- Genomic Aberrations41 topic
- Acute Lymphoblastic Leukemia31 topic
- Childhood Cancer31 topic
- Classification31 topic
- Drug Delivery31 topic
- Lymphoma31 topic
- Nanocarriers31 topic
- Dendritic Cells21 topic
- Fc Receptors21 topic
- Ferrofluids21 topic
- Immunity21 topic
- Magnetic Particle Imaging21 topic
- Therapeutic Antibodies21 topic
- Cancer11 topic
- Long Noncoding RNAs11 topic
Where does Rubén Spretz work?
Rubén Spretz's main affiliation in the publication record is LNKChemsolutions, United States.
How many publications and citations does Rubén Spretz have?
OpenAlex counts 42 works and 795 citations for Rubén Spretz, an h-index of 10, ranking #2,440,532 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Rubén Spretz. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.